コンジュゲートワクチンの世界市場:予測及び分析 2020-2024

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Parent market
• Market characteristics
• Value Chain Analysis
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market Outlook
• Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Multivalent conjugate vaccine – Market size and forecast 2019-2024
• Monovalent conjugate vaccine – Market size and forecast 2019-2024
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Increasing research activities for novel conjugate vaccine development
• Emergence of strategies to improve conjugate vaccine manufacturing
• Increasing efforts for stockpiling of conjugate vaccines
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Aurobindo Pharma Ltd.
• GlaxoSmithKline Plc
• Integrated Biotherapeutics Inc.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Pfenex Inc.
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Type – Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Multivalent conjugate vaccine – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Multivalent conjugate vaccine – Year-over-year growth 2020-2024 (%)
Exhibit 22: Monovalent conjugate vaccine – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Monovalent conjugate vaccine – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America – Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Aurobindo Pharma Ltd. – Vendor overview
Exhibit 49: Aurobindo Pharma Ltd. – Business segments
Exhibit 50: Aurobindo Pharma Ltd. – Organizational developments
Exhibit 51: Aurobindo Pharma Ltd. – Geographic focus
Exhibit 52: Aurobindo Pharma Ltd. – Key offerings
Exhibit 53: Aurobindo Pharma Ltd. – Key customers
Exhibit 54: GlaxoSmithKline Plc – Vendor overview
Exhibit 55: GlaxoSmithKline Plc – Business segments
Exhibit 56: GlaxoSmithKline Plc – Organizational developments
Exhibit 57: GlaxoSmithKline Plc – Geographic focus
Exhibit 58: GlaxoSmithKline Plc – Segment focus
Exhibit 59: GlaxoSmithKline Plc – Key offerings
Exhibit 60: GlaxoSmithKline Plc – Key customers
Exhibit 61: Integrated Biotherapeutics Inc. – Vendor overview
Exhibit 62: Integrated Biotherapeutics Inc. – Business segments
Exhibit 63: Integrated Biotherapeutics Inc. – Key offerings
Exhibit 64: Integrated Biotherapeutics Inc. – Key customers
Exhibit 65: Merck & Co. Inc. – Vendor overview
Exhibit 66: Merck & Co. Inc. – Business segments
Exhibit 67: Merck & Co. Inc. – Organizational developments
Exhibit 68: Merck & Co. Inc. – Geographic focus
Exhibit 69: Merck & Co. Inc. – Segment focus
Exhibit 70: Merck & Co. Inc. – Key offerings
Exhibit 71: Merck & Co. Inc. – Key customers
Exhibit 72: Mitsubishi Tanabe Pharma Corp. – Vendor overview
Exhibit 73: Mitsubishi Tanabe Pharma Corp. – Business segments
Exhibit 74: Mitsubishi Tanabe Pharma Corp. – Organizational developments
Exhibit 75: Mitsubishi Tanabe Pharma Corp. – Geographic focus
Exhibit 76: Mitsubishi Tanabe Pharma Corp. – Key offerings
Exhibit 77: Mitsubishi Tanabe Pharma Corp. – Key customers
Exhibit 78: Pfenex Inc. – Vendor overview
Exhibit 79: Pfenex Inc. – Business segments
Exhibit 80: Pfenex Inc. – Organizational developments
Exhibit 81: Pfenex Inc. – Key offerings
Exhibit 82: Pfenex Inc. – Key customers
Exhibit 83: Pfizer Inc. – Vendor overview
Exhibit 84: Pfizer Inc. – Business segments
Exhibit 85: Pfizer Inc. – Organizational developments
Exhibit 86: Pfizer Inc. – Geographic focus
Exhibit 87: Pfizer Inc. – Segment focus
Exhibit 88: Pfizer Inc. – Key offerings
Exhibit 89: Pfizer Inc. – Key customers
Exhibit 90: Sanofi – Vendor overview
Exhibit 91: Sanofi – Business segments
Exhibit 92: Sanofi – Organizational developments
Exhibit 93: Sanofi – Geographic focus
Exhibit 94: Sanofi – Segment focus
Exhibit 95: Sanofi – Key offerings
Exhibit 96: Sanofi – Key customers
Exhibit 97: Serum Institute of India Pvt. Ltd. – Vendor overview
Exhibit 98: Serum Institute of India Pvt. Ltd. – Product segments
Exhibit 99: Serum Institute of India Pvt. Ltd. – Organizational developments
Exhibit 100: Serum Institute of India Pvt. Ltd. – Key offerings
Exhibit 101: Serum Institute of India Pvt. Ltd. – Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 108: Validation techniques employed for market sizing
Exhibit 109: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様